Compare ETON & TIL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ETON | TIL |
|---|---|---|
| Founded | 2017 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 498.8M | 74.7M |
| IPO Year | 2018 | 2021 |
| Metric | ETON | TIL |
|---|---|---|
| Price | $16.48 | $7.08 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 5 |
| Target Price | $29.67 | ★ $100.67 |
| AVG Volume (30 Days) | ★ 207.6K | 182.7K |
| Earning Date | 11-06-2025 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $70,316,000.00 | N/A |
| Revenue This Year | $107.23 | N/A |
| Revenue Next Year | $29.72 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 102.77 | N/A |
| 52 Week Low | $11.09 | $5.67 |
| 52 Week High | $23.00 | $42.79 |
| Indicator | ETON | TIL |
|---|---|---|
| Relative Strength Index (RSI) | 47.89 | 30.02 |
| Support Level | $15.83 | $5.67 |
| Resistance Level | $17.17 | $12.91 |
| Average True Range (ATR) | 0.63 | 0.75 |
| MACD | 0.04 | -0.23 |
| Stochastic Oscillator | 44.81 | 19.75 |
Eton Pharmaceuticals Inc is a United States based specialty pharmaceutical company. The company is engaged in developing and commercializing pharmaceutical products to fulfill an unmet patient need. It has four commercial rare disease products, Alkindi Sprinkle for the treatment of adrenocortical insufficiency; Carglumic Acid for the treatment of hyperammonemia, Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of hereditary tyrosinemia type 1 (HT-1). The Company has three additional product candidates in late-stage development: ET-400, ET-600, and ZENEO hydrocortisone autoinjector.
Instil Bio Inc is a clinical-stage biopharmaceutical company focused on developing a cell therapy pipeline of autologous tumor infiltrating lymphocyte, or TIL, therapies for the treatment of patients with cancer. It is also engaged in developing a novel class of genetically engineered TIL therapies using its Co-Stimulatory Antigen Receptor, or CoStAR, platform. Its pipeline includes ITIL-306 which expresses a CoStAR molecule designed to recognize, a tumor-associated antigen that is expressed on numerous solid tumors, including ovarian cancer, uterine cancer, NSCLC, and renal cancer.